Tobacco Center Faculty Blog

November 29, 2017

Stanton A. Glantz, PhD

My colleagues at the UCSF TCOS just put this public comment in on Phlilip Morris' MRTP application for IQOS.  The tracking number is 1k1-902j-m8kv.  A PDF of the comment is available here.
 
Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical studies to describe exposure to toxicants during dual use with other tobacco products, FDA must deny PMI’s application
 
Gideon St.Helen, PhD1,2; Peyton Jacob III, PhD1,2; Natalie Nardone, PhD1,2;
Neal L. Benowitz, MD1,2,3
1Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco; 2UCSF Tobacco Center of Regulatory Science; 3Department of Bioengineering and Therapeutic Sciences, University of California San Francisco
Docket Number: FDA-2017-D-3001
November 29, 2017
 

November 28, 2017

Stanton A. Glantz, PhD

I submitted my article in The Conversation, "Philip Morris hides data in plain sight on dangers of new heat-not-burn product" to the FDA as a public comment.  The tracking number is 1k1-902e-4bhc.  You can read the article here.

November 28, 2017

Stanton A. Glantz, PhD

I just published this article on The Conversation.
 
For as long as smoking has been known to cause cancer and other diseases, Big Tobacco has worked to avoid the truth about its deadly and highly addictive products.
 
Nicotine is the addictive drug in tobacco. Burning the tobacco generates an aerosol of ultrafine particles that carries nicotine deep into smokers’ lungs, where it is absorbed and rapidly reaches the brain. That burning yields toxic chemicals that cause disease.
 
Ever since people started understanding in the 1950s that smoking kills, millions have struggled to stop smoking. The tobacco companies, desperate to keep and expand their customers, have been trying to make “safer cigarettes” since the 1960s.
 

November 28, 2017

Stanton A. Glantz, PhD

We just submitted this public comment on California's proposed regulations on medical marijuana labeling and formulations.  A PDF of the comment which includes the graphic elements is available here.
 
Instructions for submitting public comments on emergency cannabis regulations: https://oal.ca.gov/commenting-on-emergency-cannabis-regulations/.
Link to CDPH Notice: https://www.cdph.ca.gov/Programs/OLS/Pages/DPH-17-010E-Emergency-Cannabis-Regulations.aspx
Link to CDPH emergency regulations:  https://www.cdph.ca.gov/Programs/OLS/CDPH%20Document%20Library/DPH-17-010E_ER_RegText_Application.pdf
 
 
Comment on Proposed Regulation:
DPH-17-010E
Cannabis Manufacturing License
November 16, 2017
 
Daniel G. Orenstein, JD, MPH
Postdoctoral Fellow
 
Candice M. Bowling, JD, MPA
Postdoctoral Fellow
 
Stanton A. Glantz, PhD

November 28, 2017

Stanton A. Glantz, PhD

We just submitted this public comment on California’s Bureau of Medical Cannabis Control’s proposed emergency regulations for legalized medical marijuana sales.   A  PDF of the comment is here.
 
Instructions for submitting public comments on emergency cannabis regulations: https://oal.ca.gov/commenting-on-emergency-cannabis-regulations/.
Link to BCC Notice: http://www.bcc.ca.gov/law_regs/bcc_emerg_rulemaking.pdf
Link to BCC emergency regulations: http://www.bcc.ca.gov/law_regs/bcc_prop_text_reg.pdf
 
 
Comment on Proposed Regulation
 
CALIFORNIA CODE OF REGULATIONS TITLE 16, DIVISION 42
BUREAU OF MEDICAL CANNABIS REGULATION

November 16, 2017
 
Candice Bowling, JD, MPA[i]
Postdoctoral Fellow
 
                                                     Daniel G. Orenstein, JD, MPH[ii]

Pages